A 6-month, randomized, double-masked, placebo-controlled study evaluating the effects of the protein kinase C-beta inhibitor ruboxistaurin on skin microvascular blood flow and other measures of diabetic peripheral neuropathy - PubMed (original) (raw)
Randomized Controlled Trial
. 2007 Apr;30(4):896-902.
doi: 10.2337/dc06-1699.
Affiliations
- PMID: 17392551
- DOI: 10.2337/dc06-1699
Randomized Controlled Trial
A 6-month, randomized, double-masked, placebo-controlled study evaluating the effects of the protein kinase C-beta inhibitor ruboxistaurin on skin microvascular blood flow and other measures of diabetic peripheral neuropathy
Carolina M Casellini et al. Diabetes Care. 2007 Apr.
Abstract
Objective: Diabetes leads to protein kinase C (PKC)-beta overactivation and microvascular dysfunction, possibly resulting in disordered skin microvascular blood flow (SkBF) and other changes observed in diabetic peripheral neuropathy (DPN) patients. We investigate the effects of the isoform-selective PKC-beta inhibitor ruboxistaurin mesylate on neurovascular function and other measures of DPN.
Research design and methods: Endothelium-dependent and C fiber-mediated SkBF, sensory symptoms, neurological deficits, nerve fiber morphometry, quantitative sensory and autonomic function testing, nerve conduction studies, quality of life (using the Norfolk Quality-of-Life Questionnaire for Diabetic Neuropathy [QOL-DN]), and adverse events were evaluated for 20 placebo- and 20 ruboxistaurin-treated (32 mg/day) DPN patients (aged > or =18 years; with type 1 or type 2 diabetes and A1C < or =11%) during a randomized, double-masked, single-site, 6-month study.
Results: Endothelium-dependent (+78.2%, P < 0.03) and C fiber-mediated (+56.4%, P < 0.03) SkBF at the distal calf increased from baseline to end point. Significant improvements from baseline within the ruboxistaurin group were also observed for the Neuropathy Total Symptom Score-6 (NTSS-6) (3 months -48.3%, P = 0.01; end point -66.0%, P < 0.0006) and the Norfolk QOL-DN symptom subscore and total score (end point -41.2%, P = 0.01, and -41.0, P = 0.04, respectively). Between-group differences in baseline-to-end point change were observed for NTSS-6 total score (placebo -13.1%; ruboxistaurin -66.0%, P < 0.03) and the Norfolk QOL-DN symptom subscore (placebo -4.0%; ruboxistaurin -41.2%, P = 0.041). No significant ruboxistaurin effects were demonstrated for the remaining efficacy measures. Adverse events were consistent with those observed in previous ruboxistaurin studies.
Conclusions: In this cohort of DPN patients, ruboxistaurin enhanced SkBF at the distal calf, reduced sensory symptoms (NTSS-6), improved measures of Norfolk QOL-DN, and was well tolerated.
Trial registration: ClinicalTrials.gov NCT00190970.
Similar articles
- Endothelial and neural regulation of skin microvascular blood flow in patients with diabetic peripheral neuropathy: effect of treatment with the isoform-specific protein kinase C beta inhibitor, ruboxistaurin.
Brooks B, Delaney-Robinson C, Molyneaux L, Yue DK. Brooks B, et al. J Diabetes Complications. 2008 Mar-Apr;22(2):88-95. doi: 10.1016/j.jdiacomp.2007.07.002. J Diabetes Complications. 2008. PMID: 18280438 Clinical Trial. - Treatment of symptomatic diabetic peripheral neuropathy with the protein kinase C beta-inhibitor ruboxistaurin mesylate during a 1-year, randomized, placebo-controlled, double-blind clinical trial.
Vinik AI, Bril V, Kempler P, Litchy WJ, Tesfaye S, Price KL, Bastyr EJ 3rd; MBBQ Study Group. Vinik AI, et al. Clin Ther. 2005 Aug;27(8):1164-80. doi: 10.1016/j.clinthera.2005.08.001. Clin Ther. 2005. PMID: 16199243 Clinical Trial. - Inhibition of PKC beta by oral administration of ruboxistaurin is well tolerated and ameliorates diabetes-induced retinal hemodynamic abnormalities in patients.
Aiello LP, Clermont A, Arora V, Davis MD, Sheetz MJ, Bursell SE. Aiello LP, et al. Invest Ophthalmol Vis Sci. 2006 Jan;47(1):86-92. doi: 10.1167/iovs.05-0757. Invest Ophthalmol Vis Sci. 2006. PMID: 16384948 Clinical Trial. - Ruboxistaurin, a protein kinase C beta inhibitor, as an emerging treatment for diabetes microvascular complications.
Joy SV, Scates AC, Bearelly S, Dar M, Taulien CA, Goebel JA, Cooney MJ. Joy SV, et al. Ann Pharmacother. 2005 Oct;39(10):1693-9. doi: 10.1345/aph.1E572. Epub 2005 Sep 13. Ann Pharmacother. 2005. PMID: 16160002 Review. - [Protein kinase C beta-Inhibitor ruboxistaurin].
Musch A. Musch A. Med Monatsschr Pharm. 2005 Aug;28(8):292-3. Med Monatsschr Pharm. 2005. PMID: 16128544 Review. German. No abstract available.
Cited by
- PKC Inhibition Improves Human Penile Vascular Function and the NO/cGMP Pathway in Diabetic Erectile Dysfunction: The Role of NADPH Oxidase.
El Assar M, La Fuente JM, Sosa P, Fernández A, Pepe-Cardoso AJ, Martínez-Salamanca JI, Rodríguez-Mañas L, Angulo J. El Assar M, et al. Int J Mol Sci. 2024 Mar 7;25(6):3111. doi: 10.3390/ijms25063111. Int J Mol Sci. 2024. PMID: 38542085 Free PMC article. - A muscarinic receptor antagonist reverses multiple indices of diabetic peripheral neuropathy: preclinical and clinical studies using oxybutynin.
Casselini CM, Parson HK, Frizzi KE, Marquez A, Smith DR, Guernsey L, Nemmani R, Tayarani A, Jolivalt CG, Weaver J, Fernyhough P, Vinik AI, Calcutt NA. Casselini CM, et al. Acta Neuropathol. 2024 Mar 25;147(1):60. doi: 10.1007/s00401-024-02710-4. Acta Neuropathol. 2024. PMID: 38526612 Clinical Trial. - An Update on Protein Kinases as Therapeutic Targets-Part I: Protein Kinase C Activation and Its Role in Cancer and Cardiovascular Diseases.
Silnitsky S, Rubin SJS, Zerihun M, Qvit N. Silnitsky S, et al. Int J Mol Sci. 2023 Dec 18;24(24):17600. doi: 10.3390/ijms242417600. Int J Mol Sci. 2023. PMID: 38139428 Free PMC article. Review. - Riluzole, a neuroprotective agent, preserves erectile function following bilateral cavernous nerve injury in male rats.
Barut EN, Engin S, Yasar YK, Sezen SF. Barut EN, et al. Int J Impot Res. 2024 May;36(3):275-282. doi: 10.1038/s41443-023-00680-x. Epub 2023 Feb 14. Int J Impot Res. 2024. PMID: 36788353 - Detection of sudomotor alterations evaluated by Sudoscan in patients with recently diagnosed type 2 diabetes.
García-Ulloa AC, Almeda-Valdes P, Cuatecontzi-Xochitiotzi TE, Ramírez-García JA, Díaz-Pineda M, Garnica-Carrillo F, González-Duarte A, Narayan KMV, Aguilar-Salinas CA, Hernández-Jiménez S; CAIPaDi Study Group. García-Ulloa AC, et al. BMJ Open Diabetes Res Care. 2022 Dec;10(6):e003005. doi: 10.1136/bmjdrc-2022-003005. BMJ Open Diabetes Res Care. 2022. PMID: 36521878 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical